To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@nih.gov along with the following information:

Your name, title, and organization
Study Number and Study Title
The specific dataset(s) you are requesting
The intended use or purpose of the data
Willingness to comply with the NIDA Datashare Registration Agreement

Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CPU-0004

Division

DTMC

HEAL Study

Investigator(s)

Kathryn Cunningham, Ph.D.

John Grabowski, Ph.D.

Title

Study of Interactions Between GBR 12909 and Cocaine

Short Description

This is a human laboratory clinical pharmacology study that will assess potential interactions between intravenous (i.v.) cocaine and three escalating oral doses (50, 70 and 100 mg) of GBR 12909, which is 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride.

Release Date

May 23, 2017

Description

The primary objective of this study is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with i.v. cocaine infusions of 20 and 40 mg by measuring adverse events and cardiovascular responses [heart rate (HR), blood pressure (BP), and electrocardiogram (ECG)]. Note: A significant interaction is defined as: more than 50% of the subjects treated with GBR 12909 experience a pharmacodynamic interaction when challenged with cocaine, which brings the stopping criteria (section 12.4.5) into effect.

Keywords

Assessments

Addiction Research Center Inventory

Barratt Impulsiveness Scale

Beck Depression Inventory

Blood Cocaine Level

Blood Study Agent Level